Affordable Access

3TC rules change again.

Type
Published Article
Journal
GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies
Publication Date
May 01, 1995
Volume
9
Issue
5
Pages
2–2
Identifiers
PMID: 11362412
Source
Medline
License
Unknown

Abstract

Last month Glaxo limited the number entering the expanded access program for its experimental anti-HIV drug 3TC to only 350 participants per week. This change was made after Glaxo announced supply problems. In addition, individuals must now have a CD4 count of 100 or less, and their count must be verified by a copy of a laboratory report. These changes give priority to those with the greatest need for new therapy.

Report this publication

Statistics

Seen <100 times